Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)
January 24, 2023 03:52 PM EST
Pharma

J&J re­it­er­ates 2025 sales goal de­spite loom­ing Ste­lara ex­clu­siv­i­ty loss, glob­al eco­nom­ic chal­lenges

Paul Schloesser

Associate Editor

John­son & John­son is dou­bling down on a mid-decade phar­ma sales goal, and it’s plot­ting a way even as it los­es ex­clu­siv­i­ty on one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times